SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Galagen(ggen)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jonathan Rothschild who wrote (7)12/4/1997 12:15:00 PM
From: Dan Turner  Read Replies (1) of 69
 
Thanks for the heads-up on ICCC. From what little research I've done on it so far (and my broker) I suppose one could argue that ICCC is a better value based on past revenues. But, in those areas where their products overlap, it seems pretty clear that GGEN is both farther along and with a superior product, based on the fact that GGEN's process increases the density of antibodies severalfold and some GGEN drug-type products are well into clinical trials. It also seems to me that the two companies are not competitors in most areas. I certainly haven't researched ICCC as thoroughly as I have GGEN, so my judgment may be premature, but it does look to me at this point that GGEN has, by far, the greater potential. I'm impressed with the quality of the people at GGEN and their contacts, among other things. I don't know about ICCC.

FWIW.

-DT
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News